Notice Concerning Change of Representative Executive Officer
14.1.2026 08:14:00 CET | Business Wire | Press Release
H.U. Group Holdings, Inc. (the Company) today announced that it has resolved, at a meeting of the Board of Directors held on January 14, 2026, to change the Company’s Representative Executive Officer as described below.
1. Name and job titles of newly appointed Representative Executive Officer
Name | New title | Current title |
Goki Ishikawa |
Representative Executive Officer,
| Managing Executive Officer |
2. Name and job titles of retiring Representative Executive Officer
Name | New title | Current title |
Shigekazu Takeuchi | Director and Executive Officer | Director, Representative Executive Officer, Chairman, President and Group CEO |
3. Reason for change
In May 2025, toward realizing its Vision for 2035, the Company announced its Medium-Term Management Plan “H.U. 2030” (MMP) as well as its CEO succession plan including the timing for the selection of the next CEO. As the succession plan progressed, the Company has recognized that Mr. Goki Ishikawa is the best to lead the execution of MMP as CEO considering he has made significant contributions to the growth of the H.U. Group as an Executive Officer in charge of IVD, which led to the resolution.
4. Career summary of newly appointed Representative Executive Officer
Name : Goki Ishikawa
Date of birth : November 18, 1976
Number of shares held : 20,100 shares (As of June 2025)
Career summary :
Mar. 1999 | University of Tokyo, B.A. Economics |
Apr. 2000 | Joined the Japan Defense Agency (currently Ministry of Defense, Japan) |
Jun. 2006 | Harvard Business School, M.B.A. |
Sep. 2006 | Joined the Boston Consulting Group |
Dec. 2008 | Joined Elsevier |
Jan. 2012 | Joined the Company |
Jun. 2013 | Director, Fujirebio Diagnostics Inc. (incumbent) |
Apr. 2014 | Director, FUJIREBIO INC. |
Jun. 2014 | Director, Fujirebio Europe N.V. (incumbent) |
Mar. 2015 | Representative Director, FUJIREBIO INC. |
Apr. 2016 | Representative Managing Director, FUJIREBIO INC. |
Apr. 2017 | Executive Vice President & Representative Director, FUJIREBIO INC. Executive Vice President & Representative Director, Fujirebio Holdings, Inc. |
Jun. 2018 | President & CEO, FUJIREBIO INC. |
Jun. 2020 | Executive Officer of the Company President & CEO, Fujirebio Holdings, Inc. (incumbent) Director, FUJIREBIO INC. (incumbent) |
Jun. 2023 | Director, SRL, Inc. (incumbent) |
Jun. 2025 | Managing Executive Officer of the Company (incumbent) |
5. Scheduled date of assuming office
April 1st, 2026
View source version on businesswire.com: https://www.businesswire.com/news/home/20260113958830/en/
Contacts
For media:
Public Relations Section, Public Relations/Sustainability Dept.
Phone: +81-3-6279-0884
Email: pr@hugp.com
For investors and analysts:
IR/SR Dept.
Phone: +81-3-6279-0926
Email: ir@hugp.com
(c) 2024 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
IQM Delivers Fourth Quantum Computer in Finland, Operational at Aalto University11.3.2026 11:32:00 CET | Press Release
IQM Quantum Computers, the global leader in deployed on-premises, full-stack superconducting quantum computers, today announced the launch of Aalto Q20 quantum computer in Finland, reinforcing its commercial leadership in the quantum industry. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260311215316/en/ Ribbon cutting of the Aalto Q20 quantum computer delivered by IQM. The 20-qubit system, which is operational at Aalto University, is the fourth quantum computer deployed by IQM in Finland, marking a milestone in the country’s growing quantum technology ecosystem. Finland has recently been characterized as the number two global quantum cluster and is amongst the top five countries for quantum patent applications. “When institutions like Aalto University own their quantum computers, it means their data, their IP, and their expertise stay theirs. That’s not a feature — that’s a strategic posture to enable world-class research
Chiesi and Bespak Partner to Advance Carbon Minimal Inhaler Production With UK Manufacturing Site11.3.2026 11:00:00 CET | Press Release
Chiesi Group ("Chiesi"), the international research focused biopharmaceutical company and a certified B Corp, and Bespak, the specialist inhalation CDMO focused on pulmonary and nasal drug delivery, today announced an expansion of their long-standing partnership, increasing pressurized metered dose inhaler (pMDI) manufacturing capacity at Bespak’s Holmes Chapel site to support the next phase of Chiesi’s Carbon Minimal Inhaler (CMI) program. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260311319953/en/ Chiesi Group ("Chiesi"), the international research focused biopharmaceutical company and a certified B Corp, and Bespak, the specialist inhalation CDMO focused on pulmonary and nasal drug delivery, today announced an expansion of their long-standing partnership, increasing pressurized metered dose inhaler (pMDI) manufacturing capacity at Bespak’s Holmes Chapel site to support the next phase of Chiesi’s Carbon Minimal Inhaler
NTT DATA Unveils NVIDIA-Powered Enterprise AI Factories to Support Secure AI Adoption and Help Clients Drive Measurable ROI11.3.2026 11:00:00 CET | Press Release
NTT DATA, a global leader in AI, digital business and technology services, announced an initiative to deliver NVIDIA-powered enterprise AI factories that drive innovation and operational excellence for organizations worldwide. NTT DATA’s new enterprise AI factories provide full-stack, domain-specific solutions that integrate data, infrastructure, workflows and governance to give organizations a repeatable and production-ready operating model for enterprise AI. NTT DATA enterprise AI factories, powered by NVIDIA, are adaptive, intelligent and automated ecosystems designed to help clients accelerate return on investment by scaling enterprise AI efficiently and managing the full AI lifecycle end to end. The company’s new enterprise AI factories integrate the NVIDIA AI infrastructure—combining GPU-accelerated computing and high-performance networking—with NVIDIA AI Enterprise software, including NVIDIA NIM microservices, to deliver high‑throughput, low‑latency AI that can be deployed consi
Haleon Strengthens Commitment to China as Consumers Focus on Better Everyday Health11.3.2026 10:00:00 CET | Press Release
Haleon, a consumer company that is solely focused on better everyday health, is investing £65 million in a new state-of-the-art oral health manufacturing site in Shanghai. The facility will support the expansion of its oral care portfolio – which includes the global brands Sensodyne and parodontax – into China’s fast-growing tier 2 and tier 3 cities, where rising incomes, growing awareness of everyday health and a shift towards trusted, branded products are reshaping consumer behaviour. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260311389622/en/ parodontax, Haleon's clinically proven gum health brand, is expanding across China As part of this shift, more consumers are embedding preventative oral care into their daily self-care routines, and demand for premium, science-backed solutions is accelerating at a rapid pace. This investment strengthens Haleon’s local manufacturing footprint and positions the business to capture
Eurofins Biomnis Launches New Clinical LC‑MS/MS Method for the Detection of Cereulide Toxin in Stool Samples11.3.2026 09:00:00 CET | Press Release
Eurofins Biomnis, a leading European provider of specialised clinical diagnostics services, and part of the global network of Eurofins laboratories, announces the successful development and validation of a new liquid chromatography tandem mass spectrometry (LC‑MS/MS) method for the detection and quantification of cereulide toxin in human stool samples. This innovation underlines Eurofins Biomnis’ diagnostic innovation, and its commitment to contributing its expertise to reducing diagnostic uncertainty with solutions that support clinicians and laboratories nationwide and internationally. Eurofins Biomnis has fully validated the method for human stool samples, taking into account matrix effects and meeting the requirements of ISO 15189 (with the exception of inter‑method comparison on pathological clinical samples). Cereulide, a toxin produced by specific strains of Bacillus cereus, has recently raised significant public attention following contamination events involving infant formula
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom